<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00079261</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-20021</org_study_id>
    <secondary_id>EORTC-20021</secondary_id>
    <nct_id>NCT00079261</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Gem-CHOP: A Randomized Phase II Study of Gemcitabine Combined With CHOP in Untreated Aggressive Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine,&#xD;
      prednisone, and gemcitabine, work in different ways to stop cancer cells from dividing so&#xD;
      they stop growing or die. Combining more than one chemotherapy drug may kill more cancer&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying giving combination chemotherapy together&#xD;
      with gemcitabine to see how well it works compared to giving combination chemotherapy alone&#xD;
      in treating patients with previously untreated aggressive stage II, stage III, or stage IV&#xD;
      non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the complete response rate (confirmed or unconfirmed) in patients with&#xD;
           previously untreated aggressive non-Hodgkin's lymphoma treated with cyclophosphamide,&#xD;
           doxorubicin, vincristine, and prednisone with vs without gemcitabine.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the safety profile of these regimens in these patients.&#xD;
&#xD;
        -  Compare the feasibility of these regimens, defined as the proportion of courses given as&#xD;
           scheduled, in these patients.&#xD;
&#xD;
        -  Compare freedom from treatment failure in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is an open-label, randomized, multicenter study. Patients are stratified&#xD;
      according to participating center, International Prognostic Index score (0-2 vs 3-5), and&#xD;
      histology (B cell vs T cell). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive CHOP chemotherapy comprising cyclophosphamide IV, doxorubicin&#xD;
           IV, and vincristine IV on day 1 and oral or IV prednisone on days 1-5.&#xD;
&#xD;
        -  Arm II: Patients receive CHOP chemotherapy as in arm I and gemcitabine IV over 30&#xD;
           minutes on days 1 and 8.&#xD;
&#xD;
      In both arms, treatment repeats every 3 weeks for 3 courses in the absence of unacceptable&#xD;
      toxicity or progressive disease. Patients achieving partial response or complete or&#xD;
      unconfirmed complete response receive an additional 5 courses of therapy (for a total of 8&#xD;
      courses).&#xD;
&#xD;
      Patients are followed every 3 months for 3 years, every 6 months for 2 years, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 76-82 patients (38-41 per treatment arm) will be accrued for&#xD;
      this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response as assessed by Cheson criteria</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by CTC 2.0</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of courses given as scheduled</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from treatment failure as assessed by Cheson criteria</measure>
  </secondary_outcome>
  <enrollment type="Actual">25</enrollment>
  <condition>Lymphoma</condition>
  <condition>Small Intestine Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHOP regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed aggressive non-Hodgkin's lymphoma (NHL) of 1 of the following&#xD;
             WHO subtypes:&#xD;
&#xD;
               -  Diffuse large B large cell lymphoma (including all clinical and morphologic&#xD;
                  variants)&#xD;
&#xD;
               -  Grade 3 follicular lymphoma&#xD;
&#xD;
               -  Extranodal T/NK cell lymphoma, nasal type&#xD;
&#xD;
               -  Enteropathy-type T cell lymphoma&#xD;
&#xD;
               -  Hepato-splenic T cell lymphoma&#xD;
&#xD;
               -  Peripheral T cell lymphoma, unspecified&#xD;
&#xD;
               -  Angioimmunoblastic lymphoma&#xD;
&#xD;
               -  Anaplastic large cell lymphoma, systemic type&#xD;
&#xD;
          -  Stage II-IV disease&#xD;
&#xD;
          -  At least 1 site of measurable disease (e.g., lymph node or lymph node mass)&#xD;
&#xD;
          -  The following subtypes are not allowed:&#xD;
&#xD;
               -  Mantle cell lymphoma&#xD;
&#xD;
               -  Burkitt's lymphoma&#xD;
&#xD;
               -  Precursor B or T cell lymphoma&#xD;
&#xD;
               -  Primary cutaneous B or T cell lymphoma&#xD;
&#xD;
          -  No CNS involvement by lymphoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 70&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC &gt; 3,000/mm^3&#xD;
&#xD;
          -  Neutrophil count &gt; 1,000/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 2.5 times normal (unless due to lymphoma)&#xD;
&#xD;
          -  ALT and AST &lt; 2.5 times normal (unless due to lymphoma)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No severe cardiac disease that would preclude study participation or limit life&#xD;
             expectancy&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  FEV_1 and DLCO â‰¥ 75% of predicted (unless due to lymphoma)&#xD;
&#xD;
          -  No severe pulmonary disease that would preclude study participation or limit life&#xD;
             expectancy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other prior or concurrent malignancy except basal cell skin cancer or carcinoma in&#xD;
             situ of the cervix&#xD;
&#xD;
          -  No severe neurologic or metabolic disease that would preclude study participation or&#xD;
             limit life expectancy&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study compliance and follow-up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent monoclonal antibodies&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior cytotoxic agents&#xD;
&#xD;
          -  No prior treatment for NHL&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igor Aurer, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Rebro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Sint-Augustinus</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Rebro</name>
      <address>
        <city>Zagreb</city>
        <zip>41000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute - Cairo</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum St. Radboud - Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL-6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Croatia</country>
    <country>Egypt</country>
    <country>France</country>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Aurer I, Eghbali H, Raemaekers J, Khaled HM, Fortpied C, Baila L, van der Maazen RW; EORTC Lymphoma Group. Gem-(R)CHOP versus (R)CHOP: a randomized phase II study of gemcitabine combined with (R)CHOP in untreated aggressive non-Hodgkin's lymphoma--EORTC lymphoma group protocol 20021 (EudraCT number 2004-004635-54). Eur J Haematol. 2011 Feb;86(2):111-6. doi: 10.1111/j.1600-0609.2010.01540.x. Epub 2010 Dec 22.</citation>
    <PMID>20942843</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>March 8, 2004</study_first_submitted>
  <study_first_submitted_qc>March 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2004</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>small intestine lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

